Gutin P H, Wilson C B, Kumar A R, Boldrey E B, Levin V, Powell M, Enot K J
Cancer. 1975 May;35(5):1398-404. doi: 10.1002/1097-0142(197505)35:5<1398::aid-cncr2820350524>3.0.co;2-c.
Forty-eight patients with primary or metastatic malignant tumors of the central nervous system (CNS) were treated with combination chemotherapy, consisting or procarbazine (100 mg/m2 X 14 days), CCNU (75 mg/m2), and vincristine (1.4 mg/m2 X 2, 1 week apart) (PCV) every 4 weeks. Most patients had undergone initial resection of primary tumors, postoperative radiotherapy, and a post irradiation interval of 3 months or more. Other patients harbored unbiopsied, newly-discovered primary or metastatic tumors. All patients were deteriorating neurologically when treatment began. Overall response rate for PCV combination therapy was 44%, no better than results obtained with single agent procarbazine or BCNU, the most effective drugs used alone in previous brain tumor chemotherapy studies.
48例原发性或转移性中枢神经系统（CNS）恶性肿瘤患者接受了联合化疗，方案为每4周使用丙卡巴肼（100 mg/m²×14天）、洛莫司汀（CCNU，75 mg/m²）和长春新碱（1.4 mg/m²×2次，间隔1周）（PCV方案）。大多数患者已接受原发性肿瘤的初始切除、术后放疗，且放疗后间隔3个月或更长时间。其他患者患有未经活检的新发现的原发性或转移性肿瘤。治疗开始时，所有患者的神经功能均在恶化。PCV联合治疗的总体缓解率为44%，并不优于单用丙卡巴肼或卡莫司汀（BCNU）的效果，而这两种药物是之前脑肿瘤化疗研究中单独使用时最有效的药物。
